Oncology Shaping the Future of Personalized Healthcare: How Cancer Drug Development Holds the Key to Success for Precision Therapeutic Approaches | Diaceutics

Oncology Shaping the Future of Personalized Healthcare: How Cancer Drug Development Holds the Key to Success for Precision Therapeutic Approaches

October 25th, 2013

Pharmaphorum media

Early in 2013, pharmaphorum filmed a round table debate exploring how developments in personalized healthcare cancer treatments are defining the future for this area beyond oncology. In this white paper, which accompanies the broader video and written media from this debate, the transcript of the full one hour discussion is provided.

In July 2013, four expert representatives from the pharma industry, diagnostics manufacturers, clinicians and patients came together to discuss the topic, ‘Oncology shaping the future of personalised healthcare’, exploring how cancer drug development holds the key to success for precision therapeutic approaches. The resultant debate was filmed and is the video is available via pharmaphorum, in addition to individual pieces with each participant. This white paper presents the transcript from the full discussion.

This white paper will allow you to: 

  •  Understand perceptions of personalized healthcare and what it has already achieved in oncology.
  •  Assess what challenges are presented within healthcare systems to its implementation.
  •  Explore how the pharma industry is adapting to accelerate personalized healthcare.
  •  Read expert perspectives on the future of this space in oncology and beyond.

Follow the link to ‘Download the white paper’: http://www.pharmaphorum.com/media/com_content/whitepaper/2001_oncology%20shaping%20the%20future%20of%20personalised%20healthcare%20oct13.pdf

Blogs

View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications